Exact(5)
The objective of the phase III GLOW2 study was to evaluate the efficacy and safety of NVA237 50 μg q.d. in patients with moderate-to-severe COPD compared with placebo and with tiotropium (as a reference comparator) over a longer treatment period of 52 weeks.
Total costs of intervention and comparator over a lifetime horizon, accounting for the costs of complications and adverse events as well as initial intervention costs.
The prefixed margin of noninferiority of +2 was specified according to recommendations that the noninferiority margin should be between one-third and one-half of the advantage of the active comparator over placebo.
Main outcome measures Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the "cardiovascular comparator") over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease.
Here, we present the results of the Phase IIb AleNephro study, which was designed to evaluate the renal effects of aleglitazar treatment in patients with T2D and more advanced kidney impairment (stage 3 chronic kidney disease [CKD]) using the PPAR-γ agonist pioglitazone as active comparator over 52 weeks.
Similar(55)
For example, it is possible that the relative effect of a treatment versus the common comparator is over-estimated in one set of trials, and under-estimated in another set of trials.
The percentage of days patients were able to perform their usual daily activities was statistically significantly higher in the QVA149 group compared with placebo and all active comparators over the 26-week treatment period (online supplementary table S3).
For the 15 49 age group, the USA was always behind the comparators over the whole period; the USA consistently diverged from the leader.
Figure 1A shows the evolution of the leader, the USA and the comparators over the period 1958 2007 for male and female life expectancy.
More events with treatment than placebo, NNH, is in plain text In active controlled trials atypical antipsychotics olanzapine (and olanzapine and fluoxetine) and quetiapine produced more weight gain than active comparators over 6 12 weeks [ 21, 43, 45], as did olanzapine in trials lasting more than 12 weeks [ 45, 47] (Table 7).
They compared the incidence of fractures in over 8100 patients treated with pioglitazone compared to over 7400 patients treated with a comparator.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com